Parkinson's disease: A major hypokinetic basal ganglia disorder

Journal of Neural Transmission

Volumn 106, Issue 5-6, 1999, Pages 443-476

  Sian, J ^c   Gerlach, M ^b   Youdim, M B H ^a   Riederer, P ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NONE

Author keywords

Basal ganglia; Dopamine; Hyperkinesia; Hypokinesia; Motor loop; Neurodegeneration; Parkinson's disease

Indexed keywords

AKINESIA; BASAL GANGLION; HUMAN; HYPERKINESIA; HYPOKINESIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; RIGIDITY; SYMPTOM; TREMOR;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; GLOBUS PALLIDUS; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE;

EID: 0032984144     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050171     Document Type: Review

References (85)

1. Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. TINS 13: 266-271
2. Alexander GE, DeLong MR, Strick PI (1986) Parallel organisation of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381
3. Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase activity in Parkinson's disease brain. Arch Neurol 32: 114-116
4. Auff E, Birkmayer W, Brücke T et al. (1987) Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study. New Trends Clin Neuropharmacol 1 (3): 149-158
5. Baron MS, Vitek JL, Bakay RAE et al. (1996) Treatment of advanced Parkinson's disease by Gpi pallidotomy: 1-year results of a pilot study. Ann Neurol 40: 355-366
6. Bernheimer H, Birkmayer W, Hornykiewicz O et al. (1973) Brain dopamine and the syndrome of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-445
7. Birkmayer W, Riederer P, Youdim MBH et al. (1975) The potentiation of the antiakinctic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303-326
8. Birkmayer W, Knoll J, Riederer P et al. (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study. J Neural Transm 64: 113-127
9. Blum-Degen D, Müller T, Kuhn W et al. (1995) Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202: 17-20
10. Braak H, Braak E, Yilmazer D et al. (1996) Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 103: 455-490
11. Brannan T, Yahr MD (1995) Comparative study of selegiline plus L-DOPA-carbidopa versus L-DOPA-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 37: 95-98
12. Carlsson A, Fornsledt B (1991) Possible mechanisms underlying the special vulnerability of dopaminergic neurones. Acta Neurol Scand 84(1336): 16-18
13. Civelli O, Bunzow JR, Grandy DK (1993) The molecular diversity of dopamine receptors. Ann Rev Pharmacol Toxicol 32: 281-307
14. Cohen G (1987) Oxygen radicals and Parkinson's disease. In: Halliwell B, Bethesda MD (eds) Oxygen radicals and tissue injury. Federation of American Societies for Experimental Biology, pp 130-135
15. Crookshank FGT (1927) Theory of influenza. In: Crookshank FG (ed) Influenza: essays by several authors. London, Heinemann, p 16
16. Dexter DT, Carter CJ, Wells FR et al. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
17. Dostrovsky JO, Davis KD, Lee L et al. (1993) Electrical stimulation-induced effects in the human thalamus. Adv Neurol 63: 219-229
18. Duvoisin RC (1986) Genetics of Parkinson's disease. Adv Neurol 45: 307-312
19. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behaviour in diseases of the extrapyramidal system. Klin Wochenschr 38: 1236-1239
20. Elizan TS, Yahr M, Moros DA et al. (1989) Selegiline use to prevent progression of Parkinson's disease. Arch Neurol 46: 1275-1279
21. Elizan TS, Yahr MD, Moros DA et al. (1990) L-Deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-DOPA therapy in Parkinson's disease: experience in 200 patients. Adv Neurol 53: 431-435
22. Fahn S (1996) Is levodopa toxic? Neurology 47 [Suppl 3]: S184-S195
23. Fahn S (1998) Welcome news about levodopa, but uncertainty remains. Ann Neurol 43: 551-554
24. Fearnley JM, Lees AJ (1990) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
25. Forno LS (1982) Pathology of Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworth Scientific, London, pp 25-40
26. Fox SH, Brotchie JM (1996) New treatments for movement disorders. TIPS 17: 339-342
27. Gerlach M, Riederer P (1993) The pathophysiological basis of Parkinson's disease. In: Szelenyi T (ed) Series of new drugs. Inhibitors of monoamine oxidase B. Birkhäuser, Basel, pp 25-50
28. Gerlach M, Riederer P (1994b) New approaches in the treatment of Parkinson's disease. In: Crommelin DJA, Midha KK, Nagai T (eds) Topics in pharmaceutical sciences. Medpharm Scientific Publishers, Stuttgart, pp 123-148
29. Gerlach M, Riederer P (1994a) Pathobiochemische Befunde bei extrapyramidal-motorischen Erkrankungen. In: Huffmann G, Braune HJ, Henn KH (eds) Extrapyramidal motorische Erkrankungen. Einhorn-Presse Verlag, Reinbek, pp 45-59
30. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparision with the phenomenology of the disease in man. J Neural Transm 103: 987-1041
31. Gerlach M, Riederer P (1999) Possible time sequences of dopaminergic cell death in Parkinson's disease. Indications for neuroprotective studies in early not late stage. Adv Neurol 70 (in press)
32. Gerlach M, Ben-Shacher D, Riederer P et al. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807
33. Gerlach M, Gsell W, Kornhuber J et al. (1996a) A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurones in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 741: 142-152
34. Gerlach M, Riederer P, Youdim MB (1996b) Molecular mechanisms for neurodegenertion: synergism between reactive oxygen species, calcium and excitotoxic amino acids. Adv Neurol 69: 177-194
35. Gerlach M, Youdim MBH, Riederer P (1996c) Pharmacology of selegiline. Neurology 47(3):S137-S145
36. Gerlach M, Blum-Degen D, Lan J, Riederer P (1999) The possible role of nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol 70 (in press)
37. Gibb WRG, Lees AJ (1988) The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 15: 27-44
38. Grafton ST, Waters C, Sutton J et al. (1995) Pallidotomy increases activity of motor association cortex in Parkinson's disease: a PET Study. Ann Neurol 37: 776-783
39. Hassler R, Riechert T (1954) Indikationen und Lokalisalionsmethode der gezielten Hirnoperationen. Nervenarzt 25: 441-441
40. Ikeda H, Markey CJ, Markey SP (1992) Search for neurotoxins structurally related to MPP+ in the pathogenesis of Parkinson's disease. Brain Res 575: 285-298
41. Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
42. Kopin I (1993) The pharmacology of Parkinson's diseases therapy: an update. Ann Rev Pharmacol Toxicol 32: 467-495
43. Kornhuber J, Weller M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135-144
44. Lange KW, Kornhuber J, Riederer P (1997) Dopamine/glutamale interactions in Parkinson's disease. Neurosci Biobehav Rev 21: 393-400
45. Langsten JW, Ballard P, Tetrud JW et al. (1983) Chronic parkinsonisms in human due to a product of mepridine-analog synthesis. Science 219: 979-980
46. Laitinen LV, Bergenheim AT, Hariz MI (1992) Leksell's postero-ventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76: 53-61
47. Lees AJ on the behalf of the Parkinson's disease research group of the United Kingdom (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. BMJ 311: 1602-1606
48. Levy R, Hazarti M-T, Herrero MV et al. (1997) Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neurosci 76: 335-343
49. Lozano AM, Lang AE, Galvez Jimenez N et al. (1995) Effect of GPi pallidotomy on motor functions in Parkinson's disease. Lancet 346: 1383-1387
50. Marsden CD (1981) Flutuations of disability in PD. Clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 96-122
51. Marsden CD (1982) The mysterious motor function of the basal ganglia: the Robert Wartenburg lecture. Neurology 32: 514-539
52. Marsden CD (1990) Parkinson's disease. Lancet 335: 948-952
53. McGeer PL, Italaski S, Boyes BE et al. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's disease and Alzheimer's disease brains. Neurology 38: 1285-1291
54. Meldrum B, Garthwaite J (1991) Excitatory amino acids and neurotoxicity and neurodegenerative diseases. In: Lodge D (ed) The pharmacology of excitatory amino acids, A TIPS special report. Elsevier, Cambridge, pp 54-62
55. Mogi M, Harada M, Kondo T et al. (1994) Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147-150
56. Murer G, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575
57. Mutch WJ, Dingwall-Fordyce I, Downie AW et al. (1986) Parkinson's disease in a Scottish city. BMJ 292: 534-536
58. Nieoullon A, Kerkerian L, Dusticier N (1983) Presynaptic controls in the neostriatum: reciprocal interactions between the nigrostriatal glutaminergic pathway. In: Massion J et al. (eds) Neural coding of motor performance. Springer, Berlin Heidelberg New York Tokyo, pp 131-140
59. Olanow CW, Godbold J, Koller WC (1996) Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 312: 702-703
60. Parkinson J (1817) An essay on the shaking palsy. Sherwood Neely & Jones, London
61. Paulus W, Jellinger R (1991) The neuropathological basis of different clinical subgroup of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
62. Perry TL, Godwin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310
63. Poirier LJ, Sourkes TL, Bouvier G, Boucher R, Carabin S (1966) Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain 89: 37-52
64. Polymeropoulos MH, Laedan C, Leroy E et al. (1997) Mutation of the α-synuclein gene identified families with Parkinson's disease. Science 276: 2045-2047
65. Rajput AH, Uitti RJ, Rajputn AH (1997) Timely levodopa administration prolongs survival in Parkinson's disease. Parkinsonism and Related Disorders 3: 159-165
66. Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit M. Parkinson. Morbus Parkinson und andere Basalganglienerkrankungen. Symposium zu einem Förderschwerpunkt des BMFT, Bad Kissingen, 23-25 April, pp 44
67. Rinne JO (1991) Nigral degeneration in Parkinson's disease in relation to clinical features. Acta Neurol Scand 84: 87-90
68. Schmidt WJ (1995) Balance of transmitter activities in the basal ganglia loops. J Neural Transm 46: 67-76
69. Sechi G, Deleda MG, Bua G et al. (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 20(7): 1159-1170
70. Sian J, Dexter DT, Cohen G et al. (1991a) Comparison of HPLC and enzymatic recycling assay for the measurement of oxidised glutathione levels in brain. Br J Pharmacol December (London meeting)
71. Sian J, Dexter DT, Jenner P et al. (1991b) Decrease in nigral glutathione in Parkinson's disease. Br J Pharmacol 104: 281P
72. Sian J, Gerlach M, Riederer P (1998) The role of altered glutathione status in the development of Parkinson's disease. In: Shaw C (ed) The role of glutathione in the central nervous system. Taylor & Francis, Bristol, pp 287-304
73. Smith AD, Bolam AD (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. TINS 13(7): 259-265
74. Sofic E, Riederer P, Heinsen H (1988) Increased iron (III) and total iron content in post-mortem substantia nigra of Parkinsonian brain. J Neural Transm 74: 199-205
75. Stangel M, Zeth UK, Edward M et al. (1996) Hydrogen peroxide and nitric oxide mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts. J Neuropathol Exp Neurol 55: 36-43
76. Tasker RR, DeCarvalho GC, Li CS et al. (1996) Does thalamotomy alter the course of Parkinson's disease? Adv Neurol 69: 563-583
77. Tatton WG, Chalmers-Redman RME (1997) Modulation of gene expression rather than monoamine oxidase inhibition: (-) deprenyl-related compounds in controlling neurodegcneration. Neurol 47: S171-S183
78. The Parkinson Study Group (1989) DATATOP: a multicenter controlled trial in early Parkinson's disease. Arch Neurol 46: 1052-1060
79. The Parkinson Study Group (1993) Effects of α-tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
80. The Parkinson Study Group (1997) Mortality in Datalop. A multi-center trial in early Parkinson's disease. Ann Neurol 43: 318-325
81. Tretiakoff C (1919) Contribution a l'etude de l'anatomie pathologique du locus niger de soemmering avec quelques deductions relatives a pathogenic des troubles du tonus musculaire et de la maladie de Parkinson. Thesis, Paris
82. Vjera A, Holthoff-Detto, Kessler J et al. (1997) Functional effects of striatal dysfunction in Parkinson's disease. Arch Neurol 54: 145-150
83. Weinmuller FB, Ulas J, Nguyen L et al. (1992) Elevated NMDA receptors in Parkinsonian striatum. Neuro Report 3: 977-980
84. Yuen EC, Molbey WC (1996) Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 40(3): 354
85. Zeevalk GD, Bernard LP, Albers DS et al. (1997) Energy stress-induced dopamine loss in glutathione peroxidase overexpressing transgenic mice and in glutathione depleted mesencephalic cultures. J Neurochem 68: 426-429